Long acting somatostatin analogue for the treatment of refractory RA
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Open therapies with the growth hormone inhibitor somatostatin in small studies demonstrated anti-inflammatory effects such as reduction of synovial membrane thickness and improved clinical symptoms such as morning stiffness and other American College of Rheumatology criteria in rheumatoid arthritis.
“Open therapies with the growth hormone inhibitor somatostatin in small studies demonstrated anti-inflammatory effects such as reduction of synovial membrane thickness [123] and improved clinical symptoms such as morning stiffness and other American College of Rheumatology criteria in RA [124,125].”
From Interaction of the endocrine system with inflammation: a function of energy and volume regulation (2014) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis.
Levine, J. D., Collier, D. H., Basbaum, A. I., Moskowitz, M. A., & Helms, C. A. (1985) · PubMed · Cited by 171 · see citing works
Substance p and arthritis: analysis of plasma and synovial fluid levels
Marshall, K. W., Chiu, B., & Inman, R. D. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330111 · Cited by 171 · see citing works
Gazelius, B., Brodin, E., Olgart, L. M., & Panopoulos, P. (1981) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1981.tb06876.x · Cited by 113 · see citing works
Paran, D., Elkayam, O., Mayo, A., Paran, H., Amit, M., Yaron, M., & Caspi, D. (2001) · Annals of the Rheumatic Diseases · doi:10.1016/s0003-4967(24)43390-6 · Cited by 56 · see citing works
Self-citationMARMINI, S., Matucci‐Cerinic, M., Geppetti, P., BIANCO, E. D., Marchesoni, A., Tosi, S., Cagnoni, M., & Partsch, G. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb33147.x · Cited by 42 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis
Dasgupta, P. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.02.002 · Cited by 166 · see citing works
Interaction of the endocrine system with inflammation: a function of energy and volume regulation
Straub, R. H. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4484 · Cited by 121 · see citing works
“Open therapies with the growth hormone inhibitor somatostatin in small studies demonstrated anti-inflammatory effects such as reduction of synovial membrane thickness [123] and improved clinical symptoms such as morning stiffness and other American College of Rheumatology criteria in RA [124,125].”
BackgroundRole of the Growth Hormone/Insulin-like Growth Factor-1 Paracrine Axis in Rheumatic Diseases
Denko, C. W., & Malemud, C. J. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.03.001 · Cited by 73 · see citing works
Neuroendocrine‐Immune Interactions
Ferone, D., Boschetti, M., Resmini, E., Giusti, M., ALBANESE, V., Goglia, U., Albertelli, M., Vera, L., BIANCHI, F., & Minuto, F. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.011 · Cited by 47 · see citing works
Somatostatin Analogs in Diagnostics and Therapy
Pawlikowski, M. (2007) · CRC Press eBooks · doi:10.1201/9781498713528 · Cited by 16 · see citing works
Zhang, Y., Huang, W., Li, F., Feng, S., Kang, K., & Xu, J. (2011) · Lupus · doi:10.1177/0961203311409268 · Cited by 8 · see citing works
Probable adverse effects of long term use of somatostatin analogues in patients with RA
Marcora, S., Lemmey, A., Maddison, P., Paran, D., & Elkayam, O. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1117 · Cited by 4 · see citing works
Self-citationThe Effects of Somatostatin on Immune Cells, Functions and Diseases
Talme, T., & Sundqvist, K. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0888-8_7 · Cited by 2 · see citing works
Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders
Assadi, M., Jokar, N., Yordanova, A., Gholamrezanezhad, A., Amini, A., Abbasi, F., Biersack, H., Amini, A. S., Nabipour, I., & Ahmadzadehfar, H. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.03.009 · Cited by 2 · see citing works
Somatostatin Involvement in Rheumatoid Arthritis
Blake, A. D., West, F. M., Ghafoor, S., & Efthimiou, P. (2007) · Current Rheumatology Reviews · doi:10.2174/157339707779815740 · Cited by 1 · see citing works
Pathogenesis and Neuroendocrine Immunology
Straub, R. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-803321-0.00002-1 · Cited by 1 · see citing works
Somatostatin Control of Immune Functions
van Hagen, P. M., Dalm, V. A. S. H., Hofland, L. J., Ferone, D., & Lamberts, S. W. J. (2004) · CRC Press eBooks · doi:10.1201/9780203021941-13
Sandostatin therapy in patients with chronic sarcoidosis.
Wilhelmina, M. C. T., Jan, A. M. V. L., Virgil, A. S. H. D., Boen, L. R. K., Martin, V. H. P., & Paul, L. A. V. D. (2017) · PubMed Central · doi:10.36141/svdld.v34i3.6143
The Effects of Somatostatin on Immune Cells, Functions and Diseases
Sundqvist, O. (2012)
Somatostatin Control of Immune Functions
Ferone, D., Lamberts, S. W. J., van Hagen, P., Hofland, L. J., & Dalm, V. A. S. H. (2004) · Informa Healthcare eBooks · doi:10.1201/9780203021941.ch10
(2015) · Elsevier eBooks · doi:10.1016/b978-0-12-803321-0.09996-1
Straub, R. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-803321-0.00003-3
- Authors
- Koseoglu, F., Koseoglu, T., Paran, D., Elkayam, O., Paran, H., Yaron, M., & Caspi, D.
- Affiliations
- Ankara Numune Eğitim ve Araştırma Hastanesi (TR)
- Corresponding author
- Koseoglu, T
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2002-06
- Volume
- 61
- Issue
- 6
- Pages
- 573
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2117239091
- Cited by
- 17
- References
- 5
- Citations by year
- 2021: 1 · 2017: 1 · 2015: 3 · 2014: 1 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- rheumatoid arthritis, refractory rheumatoid arthritis, somatostatin analogues, octreotide, substance P, neurogenic inflammation, synovial fluid, articular destruction, disease-modifying antirheumatic drugs, intra-articular injection
- MeSH terms
- Aged, Arthritis, Rheumatoid, Humans, Injections, Subcutaneous, Middle Aged, Pilot Projects, Recurrence, Octreotide, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
